<table>
<thead>
<tr>
<th>Highest Risk</th>
<th>Moderate risk</th>
<th>Lowest risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>‘Shielding’</td>
<td>‘Stringent social distancing’</td>
<td>‘Social distancing’</td>
</tr>
</tbody>
</table>

1. IBD patients who **either** have a comorbidity (respiratory, cardiac, hypertension or diabetes mellitus) **and/or** are ≥70 years old
   - **and** are on any ‘moderate risk’ therapy for IBD (per middle column) **and/or** have moderate-to-severely active disease

2. IBD patients of any age **regardless of comorbidity** and who meet one or more of the following criteria:
   - Intravenous or oral steroids ≥20 mg prednisolone or equivalent per day (only while on this dose)
   - Commencement of biologic plus immunomodulator or systemic steroids within previous 6 weeks
   - Moderate-to-severely active disease not controlled by ‘moderate risk’ treatments
   - Short gut syndrome requiring nutritional support
   - Requirement for parenteral nutrition

1. Patients on the following medications:
   - Anti-TNF (infliximab, adalimumab, golimumab, certolizumab) monotherapy
   - Biologic plus immunomodulator in **stable patients**
   - Ustekinumab
   - Vedolizumab
   - Thiopurines (azathioprine, mercaptopurine, tioguanine)
   - Methotrexate
   - Calcineurin inhibitors (tacrolimus or ciclosporin)
   - Janus kinase (JAK) inhibitors (tofacitinib)
   - Immunosuppressive trial medication
   - Mycophenolate mofetil
   - Thalidomide
   - Prednisolone <20 mg or equivalent per day

2. Patients with moderate-to-severely active disease who are not on any of the medications in this column

Patients on the following medications:
- 5ASA
- Rectal therapies
- Orally administered topically acting steroids (budesonide or beclometasone)
- Therapies for bile acid diarrhoea (colestyramine, colesevamel, colestipol)
- Anti-diarrhoeals (e.g. loperamide)
- Antibiotics for bacterial overgrowth or perianal disease

---

No specific recommendations are being made regarding IBD and pregnancy, and pregnant women with IBD are encouraged to follow the guidance available from the UK government for pregnant women in the general population.

*The UK government advises those at increased risk, but not reaching the highest risk, of severe illness from coronavirus (COVID-19) to be particularly stringent when applying social distancing recommendations.

* i.e. **at least one of** (comorbidity listed above or age ≥70 years) plus **at least one of** (therapy from middle column or moderate-to-severely active disease).

** Patients should be categorised as highest risk (requiring shielding) within 6 weeks of starting biologic if they are on concomitant immunomodulator treatment or systemic steroids, whether started simultaneously or prior to the biologic. After 6 weeks they may enter the ‘moderate’ risk category provided not meeting other highest risk criteria e.g. moderate-severe disease not controlled by treatment. Biologic plus immunomodulator in stable patients may increase risk over monotherapy but there is no specific evidence for this situation.

***As adjudged by clinical team responsible for patient care.

****Patients who have stopped biologics or immunomodulators within the preceding 3 months should also be considered as having increased risk; for drugs with a much shorter half-life (e.g. tofacitinib) we advise clinician discretion.

These guidelines were last updated by the UK IBD COVID-19 working group on 02/04/2020 and were based on expert opinion and the available evidence at the time.